ASH 2020 | Real-world outcomes following tisa-cel for R/R ALL: an intention-to-treat analysis
Sara Ghorashian, FRCPath, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, describes a retrospective, real-world intention-to-treat analysis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) assessed to be eligible for treatment with tisagenlecleucel (tisa-cel) as part of an NHS national access program in England. Clinical data from around 60 patients were systematically reviewed, allowing the analysis of disease and toxicity-related outcomes. Results from this analysis indicated that real-world outcomes were encouraging and in line with data from the pivotal ELIANA clinical trial (NCT02435849), highlighting successful delivery of tisa-cel in England. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
